What Medications Treat Symptoms of Chronic Bronchitis?

Chronic bronchitis is a persistent inflammatory condition of the bronchial airways, defined clinically by a productive cough lasting at least three months per year for two consecutive years—after excluding other causes such as asthma, bronchiectasis, or congestive heart failure. Management focuses on symptom control, reducing exacerbation frequency, and slowing disease progression.

Pharmacologic treatment is individualized based on symptom burden, exacerbation history, and lung function. First-line therapy includes short-acting bronchodilators—such as albuterol or ipratropium—for acute relief of wheezing and breathlessness. For patients with more frequent symptoms or airflow limitation, long-acting bronchodilators (e.g., tiotropium, formoterol, or indacaterol) are recommended, often in combination (e.g., LABA/LAMA dual therapy).

Inhaled corticosteroids (ICS) are not routinely indicated for chronic bronchitis alone but may be added in patients with overlapping features of asthma or frequent exacerbations despite optimized bronchodilator therapy. Antibiotics have no role in stable disease but may be prescribed during acute exacerbations when purulent sputum, increased dyspnea, and fever suggest bacterial infection.

Mucolytics—including carbocisteine and N-acetylcysteine—may reduce sputum viscosity and decrease exacerbation rates in select patients with chronic bronchitis and frequent productive cough. Phosphodiesterase-4 inhibitors like roflumilast are reserved for severe cases with chronic bronchitis phenotype and recurrent exacerbations, particularly in those with chronic obstructive pulmonary disease (COPD) and chronic bronchitis overlap.

Nonpharmacologic interventions remain foundational: smoking cessation, pulmonary rehabilitation, influenza and pneumococcal vaccination, and avoidance of environmental irritants. Treatment decisions should always be guided by comprehensive clinical assessment—not symptom-based self-medication.